搜索
 > 【IL-2】重组蛋白信息

IL-2信息

英文名称:Interleukin-2
中文名称:白细胞介素-2
靶点别称:TCGF,INN=Aldesleukin,Interleukin-2,T-cell growth factor,IL2,IL-2
上市药物数量:1
临床药物数量:6
最高研发阶段:批准上市

IL-2产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
IL2-H4113
Human
Human IL-2 Protein, Tag Free
IL2-H82F3
Human
Biotinylated Human IL-2 Protein, Fc Tag, Avi Tag

IL-2 分子别名

IL2,TCGF,lymphokine,Interleukin 2

IL-2 分子背景

Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

IL-2 参考文献

IL-2上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Thalidomide 沙利度胺 NSC-527179,K 17,NSC527179,NSC66847,K-17,NSC-66847,K17,NSC 527179,NSC 66847 批准上市 新基 THALOMID fda 多发性骨髓瘤, 麻风结节性红斑 CELGENE 1998-07-16 麻风结节性红斑, 多发性骨髓瘤 详情

IL-2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Tucotuzumab celmoleukin EMD-273066; huKS-IL2; KS-IL2 临床二期 EMD Lexigen, 默克雪兰诺 小细胞肺癌, 卵巢癌 详情
S-95007 S-95007 临床二期 施维雅 免疫炎症, 免疫性疾病
Cancer vaccine pp65 (Immunomic Therapeutics/Duke University) 临床二期 Immunomic Therapeutics, 杜克大学医学中心 成胶质细胞瘤
HBAI-20 HBAI-20; HBAI-20-CyTuVax 临床二期 CyTuVax 乙肝 详情
TG-4010 TG-4010; VV-MUC-IL2 临床三期 Transgene 非小细胞肺癌 详情
Interleukin-2 gene therapy (Valentis) 临床二期 Valentis 肺癌, 头颈癌, 黑色素瘤

消息提示

请输入您的联系方式,再点击提交!

确定